Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2009. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically detailing changes in share interests arising from dividend reinvestment.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific share transaction price of £11.45 per Ordinary share.
Material Changes
On August 4, 2009, the following individuals purchased Ordinary shares through the reinvestment of dividends within an Individual Savings Account (ISA):
- Mr A P Witty: 6 shares
- Mr J S Heslop: 7 shares
- Mr S M Bicknell: 44 shares
- Mr E J Gray: 7 shares
- Mr D S Redfern: 7 shares
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the total number of shares held by the named directors following this transaction.
- Confirm the market price of GSK shares on August 4, 2009, to validate the £11.45 transaction price.
- Review subsequent filings for any additional director transactions or changes in beneficial ownership.